DICE Therapeutics
phase study design and dose rationale dice lea ama home | DICE Therapeutics
Company
Deck Type
Deck date
October 2022
Slide
7 of 39
Similar slides by DICE Therapeutics
See diffirences between slides (animation)
Investor Presentation
March 2023
phase study design and dose rationale test active | DICE Therapeutics
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
December 2023
randomized prospective double blind placebo controlled study phase design placebo controlled road | NeuroSense Therapeutics
ATAI
Investor Presentation
January 2024
trial status first patient dosed in topline data anticipated mid clinical design phase study | ATAI
BrainStorm Cell Therapeutics
Investor Presentation
October 2022
phase trial study design designed to exclude slow | BrainStorm Cell Therapeutics
Anebulo Pharmaceuticals
Investor Day
September 2022
phase part adaptive study design | Anebulo Pharmaceuticals
Other recent decks by DICE Therapeutics
See all presentations (4 decks)
Results
March 2023
Investor Presentation
March 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io